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Abstract
Background: Low mitochondrial content and oxidative capacity are well-established features of locomotor muscle
dysfunction, a prevalent and debilitating systemic occurrence in patients with chronic obstructive pulmonary disease
(COPD). Although the exact cause is not firmly established, physical inactivity and oxidative stress are among the
proposed underlying mechanisms. Here, we assess the impact of COPD pathophysiology on mitochondrial DNA
(mtDNA) integrity, biogenesis, and cellular oxidative capacity in locomotor muscle of COPD patients and healthy
controls. We hypothesized that the high oxidative stress environment of COPD muscle would yield a higher presence
of deletion-containing mtDNA and oxidative-deficient fibers and impaired capacity for mitochondrial biogenesis.
Methods: Vastus lateralis biopsies were analyzed from 29 COPD patients and 19 healthy age-matched controls for the
presence of mtDNA deletions, levels of oxidatively damaged DNA, mtDNA copy number, and regulators of mitochondrial
biogenesis as well the proportion of oxidative-deficient fibers (detected histologically as cytochrome c oxidase-deficient,
succinate dehydrogenase positive (COX−/SDH+ )). Additionally, mtDNA copy number and mitochondrial transcription factor
A (TFAM) content were measured in laser captured COX−SDH+ and normal single fibers of both COPD and controls.
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Results: Compared to controls, COPD muscle exhibited significantly higher levels of oxidatively damaged DNA
(8-hydroxy-2-deoxyguanosine (8-OHdG) levels = 387 ± 41 vs. 258 ± 21 pg/mL) and higher prevalence of mtDNA
deletions (74 vs. 15 % of subjects in each group), which was accompanied by a higher abundance of
oxidative-deficient fibers (8.0 ± 2.1 vs. 1.5 ± 0.4 %). Interestingly, COPD patients with mtDNA deletions had
higher levels of 8-OHdG (457 ± 46 pg/mL) and longer smoking history (66.3 ± 7.5 years) than patients without
deletions (197 ± 29 pg/mL; 38.0 ± 7.3 years). Transcript levels of regulators of mitochondrial biogenesis and
oxidative metabolism were upregulated in COPD compared to controls. However, single fiber analyses of COX
−/SDH+ and normal fibers exposed an impairment in mitochondrial biogenesis in COPD; in healthy controls,
we detected a marked upregulation of mtDNA copy number and TFAM protein in COX−/SDH+ compared to
normal fibers, reflecting the expected compensatory attempt by the oxidative-deficient cells to increase
energy levels; in contrast, they were similar between COX−/SDH+ and normal fibers in COPD patients. Taken
together, these findings suggest that although the signaling factors regulating mitochondrial biogenesis are
increased in COPD muscle, impairment in the translation of these signals prevents the restoration of normal
oxidative capacity.
Conclusions: Single fiber analyses provide the first substantive evidence that low muscle oxidative capacity in
COPD cannot be explained by physical inactivity alone and is likely driven by the disease pathophysiology.
Keywords: Chronic obstructive pulmonary disease, Mitochondrial biogenesis, Mitochondrial DNA, mtDNA copy
number, Muscle oxidative impairment, Oxidative stress, COX deficiency, TFAM, Laser capture microscopy
Background
Locomotor muscle dysfunction is a disabling, extra-
pulmonary occurrence in chronic obstructive pulmonary
disease (COPD) and a major independent contributory
factor in the severe exercise intolerance experienced by
patients [1, 2]. Low muscle oxidative capacity is a well-
established aspect of this dysfunction, playing a major
role in the poor muscle endurance and high fatigability
that is typical of COPD patients [3–6]. The patho-
physiological mechanisms that underlie the loss of
muscle oxidative capacity in COPD are unclear and
likely relate to an interplay between muscle disuse and
other disease-specific contributors including inflamma-
tion, hypoxia, and oxidative stress. A precise under-
standing of contributing mechanisms is important
because patients who develop locomotor muscle dys-
function are heavier users of health-care resources and
have shorter life expectancies compared to those with
the same pulmonary disease severity with normal
muscle function [7].
Skeletal muscle oxidative capacity is highly dependent
on the quantity of functional mitochondria, which can
vary in response to physiological cues such as physical
in/activity, disease, and aging [8–12]. In COPD loco-
motor muscle, reductions in both mitochondrial density
and enzyme activities have been established [3, 4, 11],
and more recently, low mitochondrial DNA (mtDNA)
copy number has been reported [13]. These findings are
consistent with a reduction in mitochondrial biogenesis,
where levels of the key regulatory factor peroxisome
proliferator-activated receptor γ coactivator 1α (PGC-1α)
have been shown to be lower in COPD compared to
healthy locomotor muscle [5, 14]. Furthermore, protein
levels of its downstream effector, mitochondrial transcrip-
tion factor A (TFAM), have also been shown to be re-
duced in COPD locomotor muscle [14]. TFAM plays a
critical role in the transcription and replication of
mtDNA, both of which are necessary processes for the
synthesis of functional mitochondria and maintenance of
mtDNA copy number [15, 16]. Taken together, current evi-
dence suggests that disturbed expression of mitochondrial
biogenic regulatory factors may underlie the reduction in
skeletal muscle oxidative capacity in COPD [14, 17]. How-
ever, whether these alterations reflect the normal response
of muscle to reduced contractile activity associated with the
patients’ very sedentary lifestyle [18, 19] or pathologically
impaired mitochondrial biogenesis secondary to the COPD
systemic milieu of inflammation and high oxidative stress is
currently not established.
In considering potential pathophysiological mechanisms
that might compromise mitochondrial biogenesis re-
sponses, high oxidative stress is well-characterized in
COPD locomotor muscle [13, 20, 21]. In fact, muscle oxi-
dative stress has been associated with a reduced
endurance capacity of the quadriceps muscle itself in
severe COPD [22], and more recently, inverse correlations
between oxidative stress and markers of muscle oxidative
capacity have been reported in more mild COPD patients
[5]. Interestingly, although there is some evidence for oxi-
dative damage to mtDNA in COPD locomotor muscle
[13], the cellular functional consequences of this for skel-
etal muscle oxidative capacity have not been considered.
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As first established in patients with mitochondrial dis-
ease [23], and subsequently observed in healthy aging
muscle [24], accumulation of mtDNA mutations rela-
tive to wild-type mtDNA within a muscle fiber can
impair the synthesis of functional electron transport
chain complexes. The resulting cellular oxidative en-
zyme deficiency can be detected histochemically as
cytochrome c oxidase-deficient, succinate dehydrogen-
ase positive (COX−/SDH+) fibers. These fibers typic-
ally exist alongside oxidative-normal fibers within the
same muscle and occur normally in low abundance in
healthy aged muscle and in much higher abundance
in patients with primary mitochondrial disease [25,
26]. Interestingly, single fiber observations of mito-
chondrial biogenesis within these COX−/SDH+ fibers
have revealed an upregulation of mtDNA copy num-
ber and TFAM protein levels [27–29] compared to
oxidative-normal fibers, and at the whole muscle
level, this is associated with activation of the mito-
chondrial biogenesis signaling cascade [30], reflecting
an attempted compensatory response to the cellular
oxidative deficiency, noting that this response at the
single fiber level occurs despite the very sedentary be-
havior typical of patients with mitochondrial disease
[31]. Thus, comparison of the mitochondrial biogen-
esis response between normal and COX−/SDH+ fibers
could reveal whether the reduced muscle oxidative
capacity in COPD is impaired beyond that explainable
by the very low physical activity levels of these
patients.
On the basis of the above, the objectives of our study
were to evaluate in locomotor muscle of moderate-to-
severe COPD patients and healthy age-matched individ-
uals the level of oxidative stress (4-hydroxynonenal levels
for protein oxidation and 8-hydroxyguanosine for oxida-
tive DNA damage), mtDNA integrity (mtDNA deletions
and copy number), and the corresponding regulators of
mtDNA copy number and mitochondrial biogenesis
(PGC-1α, PGC-1β, NRF1, and TFAM levels) and oxidative
metabolism (peroxisome proliferator-activated receptors
(PPARs)) in whole muscle homogenate; and at the single
fiber level, the proportion of COX−/SDH+ fibers and dif-
ferences in mtDNA copy number and TFAM content be-
tween oxidatively impaired versus normal muscle fibers.
We hypothesized that COPD muscle would exhibit ele-
vated levels of oxidatively damaged DNA and altered
mtDNA integrity reflected as a higher presence of
deletion-containing mtDNA and COX−/SDH+ fibers com-
pared to healthy muscle. Furthermore, we hypothesized
that at the single fiber level, there would be a compro-
mised mitochondrial biogenesis response in the oxidative-
deficient fibers compared to healthy age-matched con-
trols. The significance of this latter hypothesis is that if
confirmed, it would demonstrate for the first time
convincing evidence that the low muscle oxidative cap-
acity in COPD muscle is not merely a consequence of
their sedentary lifestyle and instead implicate a myocellu-
lar pathology in this response.
Here, we show that COPD muscle contains a higher
abundance of oxidatively deficient fibers and alterations in
mtDNA integrity. Furthermore, using techniques appro-
priate for single fiber studies, we have demonstrated a
failed upregulation of both mtDNA copy number and the
upstream regulator TFAM protein in these oxidatively de-
ficient fibers, revealing an impairment in mitochondrial
biogenesis. Some of the results of these studies have been
previously reported in abstract form [32, 33].
Methods
Study participants
This study was approved by the Institutional Review
Board for human studies of the Montreal Chest Institute
(Montréal, QC, Canada). Twenty-nine ambulatory male
patients with moderate-to-severe COPD based on the
Global Initiative for Chronic Obstructive Lung Disease
classification of disease severity [34] were recruited from
the outpatient COPD clinic of the Montreal Chest Hos-
pital of the McGill University Health Center. Patients were
excluded if: (1) they reported an exacerbation requiring
the use of corticosteroids or antibiotics within the preced-
ing month; (2) they were on long-term oxygen therapy; (3)
they used oral corticosteroids; (4) they participated in a
pulmonary rehabilitation program within the preceding
year; and (5) they had a known comorbidity that could
interfere with our outcomes measures, including severe
cardiac, diabetes, neurologic, neuromuscular, cancer, and/
or orthopedic disease/condition. Nineteen healthy male
age-matched sedentary control subjects were recruited
through word of mouth and local advertisements (Table 1).
After obtaining written informed consent for procedures
and publishing, all participants underwent clinical and
physiological evaluation and, in a separate visit, a biopsy
of the mid-portion of the vastus lateralis muscle using the
modified Bergstrom needle method with suction [35].
Tissue for genetic analysis was snap frozen in liquid nitro-
gen, while muscle histology samples were mounted trans-
versely using tragacanth gum and frozen in liquid
nitrogen-precooled isopentane and stored at −80 °C.
Clinical and physiological evaluation
Lifetime tobacco exposure was calculated for each partici-
pant, as pack-year units, by multiplying the number of ciga-
rettes smoked per day by the number of years smoked and
dividing by 20 (*20 cigarettes per pack) [36]. Height in me-
ters and weight in kilograms were assessed on a standard
scale. Pulmonary function testing included spirometry and
whole-body plethysmography to measure forced expiratory
volume (FEV1), residual volume, total lung capacity, and
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diffusing capacity of the lung for carbon monoxide. All
values obtained were expressed as a percentage of reference
values. A symptom-limited incremental peak exercise test
was performed on an electromagnetically braked upright
cycle ergometer (Ergoline 800®) according to established
guidelines [37] to determine peak work capacity and peak
rate of oxygen consumption (VO2). Throughout this test,
electrocardiogram, ventilatory parameters, and arterial oxy-
gen saturation through finger oximetry were continuously
monitored. Values obtained were expressed as a percentage
of predicted as per Blackie et al. [36].
Quantification of DNA damage
DNA was extracted from muscle samples using a QIAgen
DNeasy Blood and Tissue Kit (QIAGEN, Valencia, CA)
according to the manufacturer’s instructions and concen-
trated to 20 mg/ml. Digest mix was prepared by adding
250 units Benzonase, 300 m units phosphodiesterase I
(Sigma-Aldrich, P-3243), and 200 units alkaline phosphat-
ase (Sigma-Aldrich, P-7923) to 5 mL Tris-HCl buffer
(20 mM, pH 7.9) containing 100 mM NaCl and 20 mM
MgCl2 (24). DNA samples (3 μg) in digest mix were incu-
bated at 37 °C for 6 h [38].
8-OHdG assay
Levels of oxidatively damaged DNA, 8-hydroxy-2-deoxy-
guanosine (8-OHdG), the nucleoside’s most sensitive to
modification by oxidative stress [39–41], were measured
using a competitive ELISA kit (DNA/RNA Oxidative Dam-
age EIA Kit, Cayman Chemicals, Ann Arbor, Michigan)
following the manufacturer’s instructions. Samples were
run in triplicates, along with a negative control and quanti-
fied using an eight-point standard curve (10–3000 pg/ml).
The concentration of 8-OHdG (pg/ul) was standardized
per total DNA content (1 μg per well).
Detection of mtDNA deletions in muscle homogenate
samples
Long-range PCR was performed to amplify a 10,774-bp
fragment of the major arc region, where the majority of
mtDNA deletions occur [42]. Reactions consisted of 1 μl
of DNA template, 5 μl reaction buffer, 8.75 μl 0.35 mM
dNTPs, 0.7 μl Expand Taq (TaKaRa), 20 uM of both for-
ward and reverse primers 10 pmol/μl (primers: forward
5′-AGA TTT ACA GTC CAA TGC TTC-3′, reverse 5′-
AGA TAC TGC GAC ATA GGG TG-3′), and 21.55 μl
dH2O. Amplification was performed on a thermal cycler
under the following conditions: 3 min at 93 °C; 30 cycles
of 93 °C for 30 s, 58 °C for 30 s, and 68 °C for 12 min;
with an additional 5 s for every cycle and then a final
extension of 11 min at 68 °C. Amplified PCR products
(consisting of full-length 10,774-bp amplicons along with
smaller amplicons with a mtDNA deletion) were visual-
ized using gel electrophoresis on a 0.7 % agarose gel
stained with SYBR Safe (Life Technologies). Fifteen mi-
croliters of the PCR product was loaded along with 0.5 μl
of loading dye, and a 1 kb + ladder (Invitrogen) was loaded
to enable estimation of the product size. The gel was run
for 150 min at 80 V, and bands were visualized on a UV
gel documentation system G: BOX (Syngene).
Myocellular oxidative capacity
Dual COX and SDH histochemistry is a technique rou-
tinely employed to detect in situ myofibers with a respira-
tory chain deficiency due to a high presence of mtDNA
mutations [43, 44]. Since mtDNA encodes three subunits
of complex IV (COX), and none of complex II (SDH),
mtDNA deletions often result in low COX activity, while
SDH activity remains unaffected [26]. As such, fibers with
normal COX activity (COX+/SDH+) will demonstrate a
brown reaction product (Fig. 2a, left panel), whereas fibers
with reduced or absent COX activity secondary to
mtDNA defects will only stain for the SDH blue reaction
product (COX−/SDH+) (Fig. 2a, mid panel).
Ten-micrometer muscle sections from 21 COPD and 14
control subjects were first incubated in COX medium
(100 μM cytochrome c, 4 mM diaminobenzidine tetrahy-
drochloride (DAB), and 2 %w/v catalase in 0.2 M phos-
phate buffer, pH 7.0) at 37 °C for 45 min. Sections were
then washed in PBS and incubated in SDH medium for CII
activity (130 mM sodium succinate, 200 μM phenazine
Table 1 Descriptive characteristics of healthy controls and
patients with COPD
Characteristics Control (n = 19) COPD (n = 29)
Age, years 68 ± 6 66 ± 5
Smoking, pack-years 3.4 ± 10.4 64.4 ± 37.1*
Weight, kg 80.1 ± 14.2 71.2 ± 17.2
Height, m 171.9 ± 4.4 169.7 ± 7.5
BMI, kg/m2 26.8 ± 3.8 28.8 ± 11.9
FEV1, % pred 107.9 ± 21.9 40.7 ± 13.9*
FEV1/FVC, % pred 78.5 ± 7.3 51.4 ± 13.9*
TLC, % pred 103.1 ± 13.3 122.2 ± 17.2*
RV, % pred 95.8 ± 37.1 172.1 ± 37.4*
DLCO, % pred 105.3 ± 14.3 53.2 ± 16.7*
Peak VO2, % pred 92.2 ± 17.4 38.4 ± 13.3*
Peak work, % pred 112.3 ± 21.6 36.5 ± 19.3*
Fiber CSA (μm2) 5684.6 ± 1328.7 5007.9 ± 1181.4
Fiber type 1, % 48.10 ± 20.3 24.0 ± 9.8*
Type II shiftersa, % 20 73*
Values presented as mean ± SD
Abbreviations: COPD chronic obstructive pulmonary disease, BMI body mass
index, FEV1 forced expiratory volume in one second , FVC forced vital capacity,
TLC total lung capacity, RV residual volume, DLCO lung diffusion capacity, CSA
cross section area
*p < 0.05
aNumber of patients with <27 % myosin heavy chain type 1 fibers
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methosulphate, 1 mM sodium azide, 1.5 mM nitroblue
tetrazolium in 0.2 M phosphate buffer, pH 7.0) at 37 °C for
45 min. Sections were washed in PBS, pH 7.4, dehydrated
in a graded ethanol series (70, 95, 2 × 100 %), cleared in Xy-
lene (Sigma-Aldrich, Saint Louis, MO, USA), and mounted
in DPX (Sigma-Aldrich, Saint-Louis, MO, USA).
Slides were imaged on a Scanscope XT digital slide
scanner (Aperio, Vista, CA, USA) and analyzed using Ima-
geJ software (http://imagej.nih.gov/ij/, National Institutes
of Health, Bethesda, MD). The total number of COX
+/SDH+, COX−/SDH+, and COX−/SDH− fibers (fibers
with reduced activity of both COX and SDH) were
counted using ImageJ (National Institutes of Health), for
the entire muscle section (average of 366 fibers per sec-
tion) in each subject by an observer blinded to the group
condition, with a subset being counted by a second
blinded observer to confirm classification.
Quantification of mtDNA copy number in muscle
homogenate and single fibers
MtDNA copy number was quantified using a standard
curve of the mitochondrial encoded NADH dehydrogen-
ase 1 region (MTND1) [45] in both homogenate muscle
and laser captured single COX-normal and COX-
deficient muscle fibers. This region of the mitochondrial
genome is in the minor arc and is therefore preserved in
95 % of cases of mtDNA deletions [42]. Samples were
run on a MTND1 TaqMan® qPCR assay with mtDNA
copy number being determined relative to the standard
curve, and then normalized to the total area of the cap-
tured cells.
The standard curve containing the MTND1 region was
generated from serial dilutions of template mtDNA (1020-
bp fragment, forward primer: 5′-TGT AAA ACG ACG
GCC AGT CAG CCG CTA TTA AAG GTT CG 3′, re-
verse 5′-CAG GAA ACA GCT ATG ACC AGA GTG
CGT CAT ATG TTG TTC-3′). The products were then
separated on a 1 % agarose gel, and the mtDNA fragment
was then extracted using a QiAquick Gel Extraction Kit
and quantified using a NanoDrop-2000 spectrophotometer
(Thermo Scientific, USA).
Groups of approximately 100 fibers per subject were
laser captured and used to determine values for the
muscle homogenate measurements with the area cap-
tured being noted. For single fiber analysis, individual
COX-normal and COX-deficient fibers (where present)
were laser captured and analyzed for mtDNA copy num-
ber. Laser capture was performed using an ArcturusXT™
LCM (Thermo Fisher Scientific) and Arcturus® CapSure®
Macro LCM caps, with identified cells being traced and
then lasered out from a pen membrane slide stained
only for SDH in order not to disrupt the qPCR protocol
[46]. DNA was then extracted from the cells using 20 μl
of lysis buffer (1 % Tween, 20 μg/μl proteinase K in
50 mM Tris HCl) and incubating at 55 °C for 4 h and
95 °C for 10 min. The MTND1 gene was amplified (for-
ward primer: 5′-CCC TAA AAC CCG CCA CAT CT-3′
and reverse 5′-GAG CGA TGG TGA GAG CTA AGG
T-3′) under the following cycle conditions: 2 min at 50 °
C, 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °
C and 60 s at 60 °C. Only samples with threshold cycle
(CT) values 3 cycles away from the no template control
were considered usable
Quantification of transcripts involved in oxidative
metabolism and mitochondrial biogenesis
Total RNA was extracted from samples using the RNeasy
Lipid Tissue Mini Kit (Qiagen), according to manufacturer’s
instructions. RNA concentration and purity (A260/A280 ra-
tios >1.8) were assessed using a spectrophotometer. RNA
(1 μg) was reverse transcribed to cDNA using qScript™
cDNA Synthesis Kit (Quanta BioSciences) according to the
manufacturer’s instructions. Primers for TFAM (forward
TGCAGGAGAAAAAGCCCTAA, reverse GCATTTGTC
CCGAGATGTTT (NCBI ref: NM_001270782.1)), PPARG-
C1alpha (PGC-1α) (forward TTTCCTTTTGCCATGGAA
TC, reverse: GAAAGAACCGCTGAACAAGC (NCBI ref:
XM_005248130.1)), PPAR gamma (PPARγ) (forward GAC-
CACTCCCACTCCTTTGA, reverse GATGCAGGCTC-
CACTTTGAT (NCBI ref: NM_005037.5)), PPAR delta
(PPARδ) (forward CCACTGACCCAACTGATCCT, re-
verse GAGGGAACCCTGCCTACTTC (NCBI ref: NM_00
1171818.1)), PPARGC1 beta (PGC-1β) (forward ACTAT
CTCGCTGACACGCAG, reverse GGCTGTACTGGTT
GGGTTCA (NCBI ref: XM_011537553.1)), NRF1 (forward
CACAGAAAAGGTGCTCAAAGGAT, reverse GGCCAC
TGCATGTGCTTCTA (NCBI ref: NM_001040110.1))
were designed with Primer 3 plus. TATA box binding pro-
tein (TBP) (primers: forward TATAATCCCAAGCGGT
TTGC-3, reverse GCTGGAAAACCCAACTTCTG (NCBI
ref: NM_001172085.1)) were used as a reference gene) was
used to quantify the mRNA. The cDNA was amplified
using Power SYBR® Green PCR Master Mix (Life Tech-
nologies) under the following conditions: 95 °C for 10 min
followed by 40 cycles of 95 °C for 15 s and 55 °C for 60 s.
All real-time PCR experiments were performed in tripli-
cates along with melt curve analysis to assess primer dimer
formation or contamination. Then, the comparative CT
method was used to calculate fold changes in expression in
the COPD groups compared with the control groups,
where ΔCT=CT of gene of interest −CT of TBP and
ΔΔCT=ΔCT of control group genes −ΔCT of COPD
group genes.
Western blot analysis
TFAM and 4-hydroxynonenal (HNE) quantification was
performed by SDS-PAGE and Western blot. Between 10
and 55 mg of muscle was homogenized with 10 volumes
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of extraction buffer (50 mM Tris base, 150 mM NaCl,
1 % Triton X-100, 0.5 % sodium deoxycolate, 0.1 %
sodium dodecyl sulfate (SDS), and 10 μl/ml of protease
inhibitor cocktail (Sigma-Aldrich)) using a MM400 robot
homogeniser (Retsch) then, incubated at 4 °C for 2 h
(shaking) and centrifuged at 12,000g for 20 min (4 °C).
The supernatant was removed, and the protein content
was assessed using the Bradford technique. Protein
samples were diluted in extraction buffer and Laemli
buffer to a final concentration of 2 μg/μl before boiling
at 95 °C for 5 min.
Fifteen micrograms of protein was loaded onto a 12 %
acrylamide gel for electrophoresis and then transferred
to polyvinylidene fluoride membranes (Life Sciences).
Membranes were then blocked in 5 % (w/v) semi-
skimmed milk for 1 h at room temperature and probed
overnight at 4 °C with mitochondrial transcription factor
A (TFAM) (Abcam) or HNE (anti-4-hydroxynonenal
antibody) in 5 % BSA. Rabbit polyclonal anti β-tubulin
(1:500) (Abcam) was used as a loading control for
TFAM analysis. Membranes were subsequently incubated
with horseradish peroxidase (HRP)-conjugated secondary
antibody (Abcam; 5 % milk) for 1 h at room temperature.
Protein bands were detected using SuperSignal™ West
Pico Chemiluminescent Substrate (Thermo Scientific) and
imaged with a G-Box Chem imaging system.
Immunofluorescence labeling
TFAM
Muscle sections were first fixed in 4 % paraformaldehyde
for 30 min. Antigen retrieval was performed by submer-
ging sections into boiling EDTA (1 mM, pH 8.0) for
1 min and the sections were then permeabalized with 0.1 %
Triton for 15 min at room temperature. Samples were then
blocked in 10 % normal goat serum (Life Technologies) for
30 min, probed for 2 h with TFAM (Abcam 1:150 dilution,
room temperature). Following three washes with PBS,
sections were incubated with Alexa Fluor 488 IgG for 1 h,
again at room temperature, washed in PBS and mounted in
ProLong gold (Life Technologies).
Myosin heavy chain
Muscle sections were blocked in 10 % normal goat
serum and incubated with the following primary
antibodies (all from Developmental Studies Hybridoma
Bank; diluted in blocking serum) for 1 h at room
temperature: BA-F8 (mouse anti-myosin heavy chain
(MHC)1 IgG2b, 1:25), Sc-71 (mouse anti-MHC2a IgG1,
1:200), and 6H1 (mouse anti-MHC2x IgM, 1:25). Fol-
lowing three washes in PBS, sections were probed
with the following secondary antibodies: Alexa Fluor
350 IgG2b (y2b) goat anti-mouse 1:500, Alexa Fluor
594 IgG1 (y1) goat anti-mouse 1:100, Alexa Fluor 488
IgM goat anti-mouse 1:500, and Alexa Fluor 488 IgG
goat anti-rabbit 1:500. Sections were then washed in
PCS and mounted using ProLong gold. Images were
captured on a Zeiss Axio Imager M2 fluorescent
microscope (Zeiss, Germany).
Statistical analyses
Statistical analysis was performed using GraphPad Prism
(GraphPad Software Inc.). Results are presented as
mean ± SEM, with significance set at P < 0.05. Data was
tested for normality using the Pearson omnibus normal-
ity test. Values more than two standard deviations away
from the mean were identified as outliers. In some cases,
it was not possible to perform all investigations on all
subjects due to tissue availability. Where this has oc-
curred, details are provided in the figure legends.
Two-way ANOVAs were used to compare mtDNA copy
number as well as TFAM protein content in single COX
−/SDH+ and COX+/SDH+ fibers between the COPD and
control groups, with Bonferroni’s post hoc tests for multiple
comparisons. The chi-square test was used on raw counts
to analyze differences in proportion of COX+/SDH+,
COX-/SDH+, and COXlow/SDHlow between the COPD and
control groups. Two group comparisons were assessed
using t test or Mann-Whitney test depending on distribu-
tion, with all tests being performed two-tailed.
Results
Participant characteristics
Characteristics of the study participants, all elderly
males, are presented in Table 1. As seen by the pulmon-
ary function testing, the COPD group had severe airflow
obstruction. Compared to the healthy controls, COPD
patients had a significantly higher smoking pack history
and lower predicted peak aerobic and work capacity. In
addition, COPD patient muscle displayed a low oxidative
phenotype as reflected by a significantly lower type 1
fiber composition compared to the controls.
Higher prevalence of oxidative damage and mtDNA
deletions in COPD muscle
The marker of oxidatively damaged proteins, 4-
hydroxynonenal (HNE) adduct (Fig. 1a), was twofold
higher in the vastus lateralis muscle of COPD pa-
tients (0.85 ± 0.13; n = 17) compared to age-matched
controls (0.43 ± 0.11; n = 10; P < 0.05; Fig. 1a). The
concentration of oxidatively damaged guanosine base
(8-OHdG) was 50 % higher in COPD patients (mean
387 ± 40 pg/μL) compared to control subjects (mean
258 ± 21 pg/μL; P < 0.04; Fig. 1b). Furthermore, these
differences in oxidative damage were associated with
a higher frequency of COPD patients exhibiting
mtDNA deletions in whole muscle homogenates
(Fig. 1c), with 21 of 29 patients (72 %) versus only 3
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out of 19 controls (16 %) harboring mtDNA deletions
P < 0.001).
Consistent with oxidative damage being an important
driver of the exacerbation of mtDNA deletion in COPD
muscle, COPD patients exhibiting mtDNA deletions had
higher levels of 8-OHdG (n = 21; mean 457 ± 46 pg/μL)
compared to COPD patients without mtDNA deletions
(n = 8; mean 197 ± 28 pg/μL, P < 0.002; Fig. 2a). Further-
more, COPD patients harboring mtDNA deletions had a
longer smoking history as measured by pack-years (COPD
patients with mtDNA deletions, 66.3 ± 7.5 years; with no
mtDNA deletions, 38.0 ± 7.3 years; P < 0.05) (Fig. 2b).
Interestingly, COPD patients harboring mtDNA deletions
had a lower maximal oxygen consumption than those
without deletions (patients with mtDNA deletions, 33.7 ±
2.4 % predicted maximal VO2; patients with no mtDNA
deletions, 45.6 ± 5.6 % predicted maximal VO2; Fig. 2c).
COX-deficient fibers are more prevalent in COPD
locomotor muscle
To permit in situ characterization of fiber-to-fiber variation
in myocellular oxidative capacity, dual COX and SDH
histochemistry was performed and revealed a mosaic pat-
tern of staining with COX-deficient and COX-normal fibers
within the COPD patient muscle (Fig. 3a). We observed a
greater presence of COX−/SDH+ fibers in COPD muscle;
8.0 ± 2.1 % versus 1.5 ± 0.4 % in controls; P < 0.03; Fig. 3b),
consistent with the greater occurrence of mtDNA deletions
observed in COPD muscle. Furthermore, we also observed
a trend (P = 0.10) to greater abundance of fibers with very
low levels of both COX and SDH activities (COXlow/
SDHlow) in COPD muscle compared to age-matched con-
trols (Fig. 3a, b; 7.5 ± 3.3 % in COPD vs. 1.4 ± 0.4 % in con-
trols). Taken together, COPD patients had greater levels of
respiratory-abnormal (COX−/SDH+ and COXlow/SDHlow
Fig. 1 Higher prevalence of damaged protein and DNA in COPD vastus lateralis skeletal muscle. a Higher levels of 4-hydroxynonenal (HNE)-adduct
containing proteins in COPD patients (0.85 ± 0.13; n = 17) compared to age-matched controls (0.43 ± 0.11; n = 10; *P < 0.05). b Higher concentration
of oxidatively damaged guanosine (pg of 8-OHdG per uL of total DNA) in COPD muscle (386 ± 40.64; n = 29) compared to age-matched
controls (258.0 ± 21.44; n = 16; *P < 0.01). c Representative image of long-range PCR gel demonstrating mtDNA deletions in COPD and control
subjects. Lane 1: wild-type mtDNA taken from a young adult demonstrating the full-length (10.774 kb) amplified PCR product. Lane 2: mtDNA
taken from a subject known to harbor a single mtDNA deletion resulting in an amplified product of 7.1 kb, thus demonstrating the specificity
of this technique in detecting mtDNA deletions. Lanes 3–8, 16–25, and 28–29 show the presence of deletion-containing amplicons together
with wild-type mtDNA product in most COPD subjects. Lanes 9–14 and 26–27 show the presence of the full-length wild-type mtDNA product
and deletion-containing amplicons in control subjects. Graphs show mean ± SEM
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Fig. 3 Dual COX/SDH histological staining to detect respiratory chain deficiency attributable to mtDNA deletions in vastus lateralis muscle. a Cross-
sectional images from a representative control subject demonstrating uniform, normal-COX staining (left) and a COPD patient with respiratory-deficient
fibers highlighted (red arrows, middle) as well as the lack of staining (right) reflecting depletion of mitochondria in muscle fibers. b Proportions of COX-
normal (COX+/SDH+), COX-deficient (COX−/SDH+), and mitochondria-depleted (COXlow/SDHlow) fibers presented as individual percentages in controls
(n = 14) and COPD subjects (n = 21). (Inset) Higher proportion of abnormal fibers (combined COX−/SDH+ and mitochondria-depleted fibers) in COPD
patients (957 of 8136 fibers) compared to control subjects (158 of 5182 fibers). Graphs show mean ± SEM (***P < 0.001). Scale bar is 50 μm
Fig. 2 Presence of mtDNA deletions in COPD locomotor muscle corresponds to higher levels of DNA damage, smoking history, and aerobic capacity.
a Higher levels of oxidatively damaged guanosine (pg of 8-OHdG per mL of total DNA) in COPD patients with mtDNA deletions (456.8 ± 45.7)
compared to patients without detectable mtDNA deletions (196.9 ± 28.6; ***P < 0.001). b Higher number of smoking pack-years in COPD
patients harboring mtDNA deletions (66.3 ± 7.5) compared to COPD patients without detectable mtDNA deletions (38.0 ± 7.3). c Lower
maximal oxygen consumption in COPD patients harboring mtDNA deletions (33.7 ± 2.4 % predicted) compared to COPD patients
without detectable mtDNA deletions (45.6 ± 5.6 %). Graphs show mean ± SEM (*P < 0.05)
Konokhova et al. Skeletal Muscle  (2016) 6:10 Page 8 of 16
together) fibers than controls (14.4 ± 3.7 vs. 2.9 ± 0.8 %; P <
0.05).
Depletion of mitochondrial DNA in COPD locomotor
muscle
The number of mtDNA copies measured in muscle ho-
mogenates of 15 COPD patients and 13 age-matched
controls was significantly lower (P < 0.05) in COPD (1.9
± 0.45 copies per μm2) compared to controls (5.1 ± 1.1
copies per μm2; Fig. 4a). Within individual fibers that
were laser captured (Fig. 4b), a two-way ANOVA
(group × COX status) also revealed main effects for dif-
ferences between COPD and controls, with lower copy
number in COPD, and no interaction with COX status
(copy number in COX-normal fibers: control 2.4 ± 0.42
vs. COPD 0.78 ± 0.14 copies per μm2, P < 0.05; copy
number in COX−/SDH+ fibers: controls 5.3 ± 0.89,
COPD 1.1 ± 0.23 copies per μm2, P < 0.05). Interestingly,
whereas there was a higher copy number in COX−/SDH
+ compared to COX-normal fibers in the control group
(as occurs in other conditions exhibiting such as
mtDNA disease and normal aging), this was not the case
in COPD, revealing a failed compensatory mitochondrial
biogenesis in COX−/SDH+ fibers of COPD patients. We
were unable to extract mtDNA from the COXlow/
SDHlow fibers, suggesting they had a very low mtDNA
copy number.
Abnormal expression of markers of mitochondrial
biogenesis in COPD locomotor muscle
The expression levels of important regulators of mito-
chondrial biogenesis and oxidative metabolism are
shown in Fig. 5a. A two-way ANOVA revealed a sig-
nificant main effect of subject group on levels of
mRNA (P = 0.0073; Fig. 5a) with no interaction (P =
0.061) indicating that these regulators were increased
in COPD. A significant correlation between PGC-1α
and TFAM transcript levels was observed in COPD
patients (r2 = 0.99, n = 10; P < 0.001), suggesting coor-
dinated upregulation of mitochondrial biogenic factors
in the patient group (Fig. 5b). Despite this coordi-
nated regulation, the amount of TFAM protein (con-
trol 1.0 ± 0.23, COPD 0.76 ± 0.14; P = 0.18) did not
differ between COPD and control subjects (Fig. 5c),
and the ratio of TFAM protein to TFAM transcript
was dramatically reduced in COPD patients (0.23 ±
0.06) compared to controls (0.94 ± 0.22; P < 0.05,
Fig. 5d), with the latter observation suggesting im-
paired translation of TFAM transcript to protein in
COPD muscle. Citrate synthase (CS) activity, a
marker of mitochondrial content, was lower in COPD
patients (4.6 ± 0.33 μmol per min per g muscle) than
in controls (13.4 ± 1.1 μmol per min per g muscle, P
< 0.001, Fig. 5e). Furthermore, a significant and posi-
tive correlation between TFAM and CS was found in
controls (r2 = 0.67, P < 0.01, Fig. 5f ), suggesting a co-
ordinated regulation of nuclear and mitochondrial
components of organelle biogenesis. However, there
was no relationship between CS activity and TFAM
protein in COPD patients (r2 < 0.1), where the mea-
sured levels of CS activity in COPD are 51 % lower
than predicted for the measured TFAM protein.
These latter observations suggest the TFAM protein
itself may be defective in COPD.
Fig. 4 MtDNA copy number measured by real-time PCR in vastus lateralis muscle of control and COPD subjects. a Lower mtDNA copy number in
homogenate muscle samples of COPD (1.9 ± 0.45, n = 15) compared to controls (5.1 ± 1.1, n = 13; *P < 0.05). b MtDNA copy number in single COX-
normal (COX+/SDH+; n = 12 fibers per group) and COX-deficient (COX−/SDH+; n = 13 fibers per group) muscle fibers, demonstrating an upregulation of
mtDNA copy number in COX-deficient fibers of controls (5.3 ± 0.89 compared to 2.4 ± 0.42 in COX-normal) but not in COPD muscle (1.1 ± 0.23 in COX-
deficient fibers compared to 0.78 ± 0.14 in COX-normal). Graphs show mean ± SEM (*P < 0.05)
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Abnormal TFAM expression in COX-deficient myofibers in
COPD patients
Immunofluorescent labeling for TFAM protein in individ-
ual myofibers revealed an abnormal expression pattern in
COPD locomotor muscle when compared to healthy con-
trols. In control subjects, there was a dramatic increase in
TFAM expression observed in COX-deficient myofibers,
compared to COX-normal myofibers, consistent with the
mtDNA copy number findings (Fig. 6a). In contrast, no
differences in TFAM expression were detected between
COX-deficient and COX-normal myofibers in COPD
patients (Fig. 6b). In controls, this differential pattern of
staining between COX-deficient and COX-normal fibers
was seen for both slow MHC type I- and fast MHC type
II-expressing fibers (type I COX-deficient fibers 36,553 ±
3575 A.U., COX-normal 25,510 ± 1241 A.U., P < 0.001;
type II COX-deficient fibers 24,457 ± 673.2 A.U., COX-
normal 16,007 ± 414.3, P < 0.05). In contrast, muscle fibers
from COPD patients exhibited no differences in TFAM
expression between COX-normal and COX-deficient fi-
bers of neither MHC type (type 1 COX-deficient 21,706,



























































































































































Fig. 5 Markers of mitochondrial biogenesis and oxidative metabolism in vastus lateralis muscle homogenates of COPD patients relative to controls.
a Higher levels of mitochondrial biogenesis and oxidative metabolism markers in COPD (two-way ANOVA revealed the significant main effect of disease
status, P< 0.01; TFAM and PGC-1α; COPD n= 17, controls n= 11, NRF1, PGC1β, PPAR δ, and PPAR γ; COPD n= 9 controls n= 9). b Significant correlation
between upregulated mitochondrial biogenesis signals PGC-1α and TFAM in COPD patients (r2 = 0.99, n = 10; P < 0.001). c Levels of TFAM
protein in COPD patients (0.76 ± 0.14, n = 20) and control subjects (1.0 ± 0.23, n = 10; P = 0.18) assessed by Western blot. d Lower ratio of
TFAM protein relative to TFAM mRNA in COPD patients (0.25 ± 0.07) compared to controls (0.94 ± 0.2; *P < 0.5). e Lower levels of citric
synthase activity in COPD patients (4.62 ± 0.33, n = 19) than controls (13.44 ± 1.14, n = 14; ***P < 0.001). f Positive relationship between
TFAM and CS exists in controls (r2 = 0.67, P < 0.1) but not in COPD patients (r2 < 0.1). Measured levels of CS activity in COPD are 51 %
lower than predicted for the measured TFAM protein. Graphs show mean ± SEM
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16,868 ± 1737, COX-normal 16,731 ± 652.4; Fig. 6c) corre-
sponding to a failed regulatory response across both slow
and fast muscle fibers.
Discussion
A low skeletal muscle oxidative capacity is a key feature
of COPD, and this plays a key role in the severe exercise
intolerance evident in this patient population. Despite
significant study, the causes of low muscle oxidative cap-
acity in COPD remain to be understood and consensus
has not been reached on whether this impairment is
simply a result of the very low physical activity levels
seen in these patients. As such, the purpose of our study
was to evaluate whether the high oxidative stress envir-
onment typical of COPD, wherein oxidative damage to
muscle proteins and lipids is well established, also trans-
lates to DNA, with a specific objective of quantifying the
impact on mtDNA and oxidative impairment in COPD
locomotor muscle. Consistent with our hypothesis, we
showed that COPD muscle exhibits higher levels of oxi-
datively damaged DNA and mtDNA deletions and that
this was accompanied by a higher abundance of muscle
fibers deficient in COX activity (a histological marker of
high mtDNA mutation load [24, 46, 47]). Transcripts of
mitochondrial biogenesis and oxidative metabolism were
upregulated; however, this did not result in increased
TFAM protein or mtDNA copy number. Furthermore,
by exploiting measures at the single myocyte level, we
were able to reveal that COPD patients exhibit an
impaired mitochondrial biogenesis response in these
Fig. 6 Abnormal expression pattern of TFAM protein in individual COX-deficient (COX−/SDH+) fibers of COPD locomotor muscle. a–b Representative
images of muscle immunofluorescently labeled for TFAM showing higher levels of a TFAM protein in COX-deficient fibers compared to COX-
normal fibers in vastus lateralis muscle of control subjects and b no difference in TFAM protein between COX-normal and COX-deficient fibers
in COPD patients. Slow-twitch and fast-twitch muscle fibers identified as I and II, respectively, representing myosin heavy chain (MHC) I and
MHC II fibers; scale bar is 50 μm. c Quantification of TFAM protein content in individual COX-normal (COX+/SDH+) and COX-deficient (COX
−/SDH+) fibers reveals higher content in COX-deficient compared to COX-normal slow-twitch (***P < 0.001) and fast-twitch fibers (*P < 0.05)
within control muscle, but no such difference in COPD muscle
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respiratory-deficient fibers. This latter observation pro-
vides the first substantive evidence that low muscle oxi-
dative capacity in COPD cannot be explained by very
low physical activity levels alone and is likely driven by
the COPD disease pathophysiology.
Impact of oxidative stress on nuclear and mitochondrial
DNA
Oxidative stress is well documented in COPD muscle,
with oxidative damage to lipids and proteins having been
measured most commonly [20, 48, 49]. Our results ex-
tend these findings to show for the first time that COPD
muscle also exhibits higher levels of 8-OHdG, a com-
monly occurring oxidative lesion to DNA [40, 41]. These
results are consistent with a recent study showing the
mitochondrial genome is targeted by oxidative damage
in COPD muscle [13], where a lower relative amplifica-
tion of mtDNA was reported using an assay that is
inhibited by oxidative DNA damage. Our study extends
upon these findings by revealing, through long-range
PCR, that mtDNA from COPD locomotor muscle is
more prone to deletion mutations, reporting a greater
frequency of COPD patients (72 %) exhibiting mtDNA
deletions compared to the age-matched control group
(16 %). The idea that this oxidative damage to DNA in
general (8-OHdG) and mtDNA in particular (mtDNA
deletions) is related to the high oxidative stress in COPD
is supported by the observation that patients who had
mtDNA deletions also had a higher 8-OHdG burden
and more smoking pack-years than COPD patients with-
out mtDNA deletions, noting that smoking has been
previously shown to increase 8-OHdG [50]. We also ob-
served that patients harboring mtDNA deletions had a
lower VO2max, showing a greater disease impact on aer-
obic exercise capacity in affected patients.
Consequences of mtDNA damage on cellular oxidative
capacity
Previous studies in primary mitochondrial disease and
aging have established that the presence of mtDNA mu-
tations within a muscle cell disrupts the transcription of
genes encoding mitochondrial subunits and can lead to
a respiratory chain deficiency [23–25, 27]. The manifest-
ation of a respiratory chain deficiency depends upon
unique aspects of mitochondrial genetics. Specifically,
because mitochondria contain multiple copies of
mtDNA, when mtDNA mutations are present, they usu-
ally co-exist in the cell with intact wild-type mtDNA. In
this setting, a cellular biochemical defect is expressed
when the proportion of mutated mtDNA exceeds a crit-
ical threshold, and this is exacerbated when the absolute
level of wild-type molecules is low [27, 29, 45]. Since
mtDNA encodes three subunits of complex IV (COX),
and none of complex II (SDH), a mutation in the form
of a mtDNA deletion often results in abnormal COX
activity, while SDH activity will remain unchanged or
become hyperreactive [43]. Hence, a COX−/SDH+ fiber
is a commonly used biomarker of respiratory chain defi-
ciency secondary to high mtDNA mutation load in a
variety of clinical conditions [24, 26, 46, 47]. The overall
proportion of these COX-deficient fibers was more than
five times higher (8 %) in our COPD patients than in
healthy controls, who had levels (1.5 %) consistent with
previous reports for the ages studied (up to 2 %) [26].
In addition to COX−/SDH+ fibers, we detected a
marked presence of COXlow/SDHlow fibers in COPD pa-
tients. These fibers, lacking activity of both OXPHOS
complexes, have previously been described by Gosker
and colleagues [51, 52] to exist in greater proportions in
COPD muscle compared to controls. The presence of
these fibers in healthy aging is not highly reported; how-
ever, their prevalence in COPD muscle would have func-
tional implications on muscle oxidative capacity. If we
combine COX−/SDH+ and COXlow/SDHlow fibers in our
COPD group, ~14 % of muscle fibers have negligible re-
spiratory capacity compared to less than 3 % in controls.
This level is clearly an important contributor to the
overall reduced muscle oxidative capacity that has been
established in COPD muscle as a whole. Further to these
points, quantification of mtDNA copy number revealed
a markedly reduced mtDNA copy number in both whole
muscle homogenates and in laser captured single fibers
(further elaborated upon below). These findings indicate
a lower availability of templates for transcription and
translation of the 13-mtDNA encoded respiratory chain
subunits, which is consistent with the low muscle oxida-
tive capacity in COPD. Future application of a newly de-
veloped quadruple immunofluorescent technique [53],
allowing for the quantification of key respiratory chain
subunits of complex I and IV, to muscle from COPD
patients may likely expose impairment in multiple mito-
chondrial encoded ETC complexes.
Implications of single fiber experiments in COPD muscle
A crucial question is whether the reported lower
mtDNA copy number reflects a pathological process of
COPD or is a consequence of a reduced drive on mito-
chondrial biogenesis associated with the sedentary life-
style typical of these patients. Controversy regarding the
exact contribution of a sedentary lifestyle to the low
muscle oxidative capacity in COPD has persisted [2, 54]
because recent reports have not been able to demon-
strate an association between physical activity levels and
a reduced muscle oxidative phenotype [55, 56]. More-
over, a low muscle oxidative capacity is seen in relatively
mild COPD patients [5] who do not exhibit the same
degree of sedentary lifestyle as more severely affected
patients [18, 57]. Clearly, further study is warranted
Konokhova et al. Skeletal Muscle  (2016) 6:10 Page 12 of 16
using novel approaches to this question. In view of the
heterogeneity of impact from one muscle fiber to an-
other in the context of both normal aging and mito-
chondrial disease, it seems likely that single fiber
approaches to the problem in COPD muscle may yield a
clearer understanding.
In previous studies in primary mitochondrial disease pa-
tients, mtDNA copy number and TFAM protein levels
were shown to be markedly upregulated in fibers with se-
vere oxidative impairment characterized by COX deficiency
[28, 29], demonstrating a strong drive on mitochondrial
biogenesis in these oxidatively impaired fibers. COX defi-
ciency also occurs in some fibers with normal aging, and
these fibers also exhibit upregulated mtDNA copy number
[58]. Taken together, these findings reflect a normal com-
pensatory response to the severe energy deficit in fibers
with high mtDNA mutation loads, in a futile attempt to
maintain adequate ATP levels for normal cellular function
[29]. Thus, in our current experiments, we exploited this
phenomenon as a novel way of revealing whether there is
an impaired capacity for mitochondrial biogenesis in COPD
muscle independent of their sedentary lifestyle. Specifically,
we reasoned that if mitochondrial biogenesis is impaired in
COPD muscle, COX−/SDH+ fibers in these patients should
demonstrate a limited capacity for increasing mtDNA copy
number relative to what is seen in COX−/SDH+ fibers of
healthy age-matched controls. Note that despite similarly
low VO2max (~30–50 % of age-matched predicted values)
and physical activity levels (<6000 steps per day) between
patients with mtDNA deletions [31, 59] and COPD patients
[56, 57], a robust upregulation of mtDNA copy number
and mitochondrial biogenesis is seen in the oxidative-
impaired (COX−/SDH+) fibers relative to normal fibers in
mitochondrial disease patients. Consistent with this reason-
ing, not only was there a lack of upregulation in mtDNA
copy number in these oxidatively impaired fibers of our
COPD disease patients but the COX−/SDH+ phenotype
differed from that which is seen in primary mitochondrial
disease where there is a hyperreactivity of SDH staining
reflecting the compensatory attempt to overcome the
energy deficit in these fibers. Indeed, we were not able to
detect any SDH hyperreactivity in COX−/SDH+ fibers of
our COPD muscle, further supporting the notion of failed
mitochondrial biogenesis. Thus, the fact that this response
is impaired in the oxidative-impaired fibers in COPD loco-
motor muscle argues strongly that this is a pathological al-
teration that is not related to their very sedentary lifestyle.
Whereas it has been previously suggested that the mito-
chondrial biogenesis response in COPD muscle under
basal conditions is suppressed based upon low PGC-1α
and TFAM [14], other studies suggest no impairment in
mitochondrial biogenesis based upon a normal PGC-1α
transcript response to acute exercise [13, 60]. Notwith-
standing these apparent contradictions, our new results
clearly demonstrate a deficit in mitochondrial biogenesis
in COPD muscle but that this occurs downstream of
PGC-1α and TFAM transcripts at the level of TFAM pro-
tein. Specifically, in stark contrast to the healthy controls,
we observed a lack of upregulation in TFAM protein
within the COX−/SDH+ fibers of COPD patients, and this
was independent of fiber type (Fig. 6c). Thus, whereas our
data support some aspects of the previous suggestion of a
normal mitochondrial biogenesis response in COPD
muscle by showing the coupling between PGC-1α and
TFAM transcription is maintained, in sharp contrast to a
normal response, we also show a marked uncoupling
between TFAM transcript levels and TFAM protein, sug-
gesting a problem in TFAM translation in COPD muscle.
Further to this point, whereas we observed the expected
stoichiometry between nuclear and mitochondrial compo-
nents of the mitochondrial biogenesis pathway in age-
matched controls (based upon a close relationship between
the nuclear encoded citrate synthase enzyme activity and
TFAM protein levels), there was no relationship between
these components in COPD, suggesting that even the lim-
ited TFAM protein that is available in COPD muscle may
be compromised in its function. While future studies are
needed to confirm altered TFAM function in COPD
muscle, it is known that protein oxidation can modify DNA
binding of transcription factors and make them more prone
to proteolytic degradation [61]. Therefore, direct assess-
ment of TFAM’s ability to initiate mtDNA transcription
and replication (as performed by Karamanlidis and col-
leagues [62]) is among the next important steps in under-
standing why mtDNA copy number and oxidative capacity
are low in COPD muscle.
Interestingly, in human heart failure, another disease
associated with high oxidative stress, high levels of 8-
OHdG have been associated with low levels of TFAM
protein and impaired mtDNA replication, with the
resultant mitochondrial depletion shown to be inde-
pendent of PGC-1α levels [62]. This is strikingly similar
to what we observed in our COPD patient muscle and
strongly implicates a common mechanism related to
oxidative stress. Additionally, inflammation, an upstream
mediator of oxidative stress, has also been linked to
mitochondrial abnormalities in various clinical conditions,
with a recent study reporting high levels of COX−/SDH+
fibers carrying mtDNA deletions in muscle of patients
with sporadic inclusion body myositis, a progressive my-
opathy characterized by excessive inflammation [47].
Moreover, in inclusion body myositis patient muscle, a
correlation between the level of COX−/SDH+ fibers and
the degree of T lymphocyte infiltrate was detected, leading
the authors to speculate that the chronic inflammatory en-
vironment is important in driving the mitochondrial ab-
normalities detected in this population. As such, the
evidence is accumulating that chronic inflammation,
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oxidative stress, and mitochondrial abnormalities are
linked, and further investigation into the mechanism
underlying the impairment in mtDNA replicative capacity
in COPD is certainly warranted.
Conclusions
Our current results add to previous studies documenting
the impact of oxidative damage in COPD locomotor
muscle by showing that COPD muscle exhibits higher
levels of oxidatively damaged DNA and mtDNA deletions.
Furthermore, COPD muscle exhibited an exacerbation of
the normal age-related accumulation of COX−/SDH+
muscle fibers (a histological marker of high mtDNA muta-
tion load). Following up on this observation using novel
techniques first developed for the study of the cellular
consequences of mtDNA mutations in primary mitochon-
drial disease, we showed for the first time that there is an
impaired mitochondrial biogenesis response in these
respiratory-deficient fibers in COPD muscle. The signifi-
cance of this observation is that it provides compelling
evidence that low muscle oxidative capacity in COPD is
driven by the COPD disease pathophysiology rather than
merely being the consequence of their very sedentary
behavior.
We propose that the impairment in mitochondrial bio-
genesis revealed in our study, which manifest as a com-
promised capacity for mtDNA replication in oxidatively
impaired fibers, leads to a gradual erosion of muscle oxi-
dative capacity in COPD. Furthermore, this impaired cap-
acity for mtDNA replication results in a chronically low
mtDNA copy number that in turn renders myocytes more
vulnerable to further mtDNA damage-induced oxidative
depletion in COPD (because fewer mtDNA copies mean a
faster attainment of the cellular deletion threshold for
phenotypic manifestation of the oxidative impairment) and
further exacerbates the muscle oxidative deficit and con-
tributes to impaired fatigue resistance in COPD patients.
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